Trinity Biotech plc (NASDAQ:TRIB) Sees Large Growth in Short Interest

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,900 shares, an increase of 58.3% from the March 31st total of 1,200 shares. Based on an average daily trading volume, of 94,300 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Trinity Biotech in a report on Wednesday. They set a “buy” rating on the stock.

Trinity Biotech Stock Performance

TRIB opened at $1.83 on Friday. The company’s fifty day moving average price is $2.01 and its two-hundred day moving average price is $2.24. Trinity Biotech has a 1-year low of $1.79 and a 1-year high of $5.50. The company has a market cap of $13.95 million, a price-to-earnings ratio of -0.58 and a beta of 1.21.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings data on Thursday, April 4th. The company reported ($0.68) earnings per share for the quarter. The business had revenue of $13.43 million for the quarter. As a group, equities analysts forecast that Trinity Biotech will post -1.5 earnings per share for the current fiscal year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.